Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. - Wikidata - awgldk - TriplyDB

Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb.

Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb.

http://www.wikidata.org/entity/Q33730469

about

The adenovirus genome contributes to the structural stability of the virion Promising and delivering gene therapies for vision loss Gene therapy of inherited retinal degenerations: prospects and challenges A comprehensive review of retinal gene therapy Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer Comparative analysis of DNA nanoparticles and AAVs for ocular gene delivery Structural Insights into Adeno-Associated Virus Serotype 5 Gene therapy for hemophilia Myosin7a deficiency results in reduced retinal activity which is improved by gene therapy.Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation Partial restoration of cardiac function with ΔPDZ nNOS in aged mdx model of Duchenne cardiomyopathy.Full-length dystrophin reconstitution with adeno-associated viral vectors The potential of adeno-associated viral vectors for gene delivery to muscle tissue.Deletion of the B-B' and C-C' regions of inverted terminal repeats reduces rAAV productivity but increases transgene expression Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6.Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences Vector platforms for gene therapy of inherited retinopathies.Cystic fibrosis transmembrane conductance regulator with a shortened R domain rescues the intestinal phenotype of CFTR-/- mice.Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production.Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo.Duchenne muscular dystrophy gene therapy: Lost in translation?Recombinant AAV-directed gene therapy for type I glycogen storage diseases.Natural history of cone disease in the murine model of Leber congenital amaurosis due to CEP290 mutation: determining the timing and expectation of therapy.AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models Duchenne muscular dystrophy gene therapy in the canine model.Gene Therapy of ABCA4-Associated Diseases.Gene Therapy for the Retinal Degeneration of Usher Syndrome Caused by Mutations in MYO7A Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma The evolution of heart gene delivery vectors Methods for gene transfer to the central nervous system.Identification and Validation of Small Molecules That Enhance Recombinant Adeno-associated Virus Transduction following High-Throughput Screens.In vivo gene transfer strategies to achieve partial correction of von Willebrand disease.Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients.Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy Non-viral therapeutic approaches to ocular diseases: An overview and future directions

P2860

Q26825101-48A970E8-88B7-4B7F-A999-CB4765DBE887 Q27007079-93D5B15A-B085-41A7-BAD9-102090E3C003 Q27009261-87EA2C69-E0B3-45A4-AD2E-B804EEB0AA1E Q27023914-7E79558A-A1DB-47B5-AFF0-43AECA1254DB Q27300915-5A0D8BDE-2519-4597-B2BA-5150CBAE708D Q27325842-C7D85716-3333-48D2-ABA1-9708079312EB Q27679454-C2EE39CD-F688-4751-A5DF-E08E22E1B9D8 Q28081911-EEED691A-FDFC-4F65-B173-12D3E706BF42 Q31132177-0BCC2A4F-E127-4CA1-864B-033BBC4C9D52 Q33586309-6EE8E6B2-33FD-4C5F-AA09-8DCC133A1028 Q33649295-87B3699E-3666-486A-826C-21F5EBD85802 Q33782799-122AAA09-CB7E-4CE3-96B1-C13E47C7AC10 Q33902499-1904F23F-F0CE-41BB-9B91-7735F8672BC8 Q33905659-7B5243F2-8A16-444F-BD00-E9825698C6CC Q34082003-DDF391DC-8739-4C0A-B5EE-848F00E54BAC Q34158497-2914179E-A411-4906-AB8A-C9D218ECA027 Q34218552-FBFF393B-CFF2-4C86-B86D-AF430B026888 Q34343763-578FE8FB-71F8-4B58-853C-5F628E739CAB Q34473295-42EFCFE1-1F17-4150-9C7B-5AE440B2B0F1 Q34511733-CE07BF54-4D35-4C73-9A88-DFE9FE80AABD Q34561531-4B4CA696-68F1-43F0-9B1A-11DD38D56CC5 Q34582621-BB30E9AD-3A53-4EAA-8D20-D3EE2FF93598 Q34770593-C285FE06-BDC3-40E7-8957-4FD0248B7C82 Q34991117-35851E03-1FAB-4A84-972F-279F56D57A0E Q35052506-11C995C2-AF73-4EC6-B3BE-67318452D62B Q35078590-7C7A7C63-EE1D-434C-9932-404E238B19F7 Q35132187-914D79D3-6D14-4950-8404-1EE961DACD04 Q35204883-E2329A1E-0D6A-4ECA-87A3-105ADB5D6476 Q35641673-43AD236D-0FBD-4D17-806D-7052C9BA8638 Q35663857-06FCF92B-F6F4-4F9E-843F-63073EB0D37A Q35664199-3C39FD12-D825-4E74-87FD-117F8DA460E3 Q35678415-BB9C403C-3B7C-48D8-A476-A1030F58ACC3 Q35678425-060EAA6D-13D0-4A39-AF18-8B03DED97E05 Q35799722-B786C7F4-C30B-448B-A57B-79B423EA20FA Q35902332-D0D3FB25-97D4-4165-B7C3-4DB896A9472E Q36009041-B0D1386B-B0F0-40FC-8FA5-88670A0846F6 Q36084450-7686E8CD-1545-4C1C-BD2E-3E1B08E0B54D Q36147481-425BE3E1-2CC2-4E1C-A7ED-6A94AFB85F47 Q36406869-ED67BE8D-2636-456E-BA7E-B54BEE7D4844 Q36425890-1418F211-2084-4E46-BD01-18D3778F3E3B

P2860

Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb.

http://www.wikidata.org/entity/Q33730469

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Evidence for the failure of ad ...... a viral genome > or = 8.2 kb.

@ast

Evidence for the failure of ad ...... a viral genome > or = 8.2 kb.

@en

type

label

Evidence for the failure of ad ...... a viral genome > or = 8.2 kb.

@ast

Evidence for the failure of ad ...... a viral genome > or = 8.2 kb.

@en

prefLabel

Evidence for the failure of ad ...... a viral genome > or = 8.2 kb.

@ast

Evidence for the failure of ad ...... a viral genome > or = 8.2 kb.

@en

P1433

Q33730469-1ADCC8B7-7A90-4456-99FC-491E104379FC

P1476

Q33730469-9B74BE60-EC46-4C30-AE70-1FA2D7CD911F

P2093

Q33730469-21DC47E6-29CF-4391-A0F8-16B40E04B0E0

Q33730469-3E45400B-B3B5-4CC7-92C1-D674C49645D8

Q33730469-E5C50241-4719-4FA8-BB39-57798AC48CB5

P2860

Q33730469-005F114F-9400-488D-A520-B952618B34FA

Q33730469-06C017AE-7081-4621-831C-E650E7A9DFFE

Q33730469-0C3D049B-4B71-458E-BA07-D2ED861F55D8

Q33730469-1B9547D8-E7C0-40AD-81A7-E63E37035DBA

Q33730469-1C55B71D-479C-4F68-91C1-7C468A641F95

Q33730469-237741E3-3879-4CBB-BF15-1484993A2592

Q33730469-2CA8813E-8374-4814-B01C-003A2DF2E95A

Q33730469-2CC54C91-C869-405D-82DD-C1DB909FD814

Q33730469-2E625565-7AA0-4033-B1DE-7795B7FCA630

Q33730469-344E4691-8BDB-49C7-9FA2-8A4F48F39CD4

P304

Q33730469-BA106367-2EA4-4E52-8915-BF4FE364F895

P31

Q33730469-B2860426-4147-4350-9C74-D21830E66F29

P356

Q33730469-1CAD62BA-385E-4AEE-8163-7C0634785EA3

P433

Q33730469-EBE30745-98E2-4770-8FFE-1EADC7F35A41

P478

Q33730469-1BC17810-DD76-4F83-9B0E-610601AF7B81

P577

Q33730469-90BC35C5-AF15-4544-BFF2-A544C1A4E783

P5875

Q33730469-A739CE00-68A7-4F58-9D98-2AE0132BEFA8

P698

Q33730469-C925B3F9-50D3-49CD-8561-A337B77A3C2A

P932

Q33730469-2E30F980-D83F-41F9-9925-6520CAEB6201

P356

P1433

Molecular Therapy

P1476

Evidence for the failure of ad ...... a viral genome > or = 8.2 kb.

@en

P2093

Dongsheng Duan

http://www.w3.org/2001/XMLSchema#string

Yi Lai

http://www.w3.org/2001/XMLSchema#string

Yongping Yue

http://www.w3.org/2001/XMLSchema#string

P2860

Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue.

Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.

Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus

Vision 1 year after gene therapy for Leber's congenital amaurosis

Safety and efficacy of gene transfer for Leber's congenital amaurosis

Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis

A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner

Effect of gene therapy on visual function in Leber's congenital amaurosis

Investigation of the cause of death in a gene-therapy trial.

Characterization of genome integrity for oversized recombinant AAV vector.

P304

75-79

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2009.256

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38080833

http://www.w3.org/2001/XMLSchema#string

P698

19904238

http://www.w3.org/2001/XMLSchema#string

P932

2839223

http://www.w3.org/2001/XMLSchema#string